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Workers Exposed to Hazardous Drugs
Summary
Healthcare workers who prepare, 
administer, or transport hazardous 
drugs or dispose of hazardous drug 
waste may face risks to their own 
health such as skin disorders, re­
productive disorders, and possibly 
cancer. NIOSH recommends that 
employers establish a medical sur­
veillance program as part of a com­
prehensive prevention program  
that also minimizes worker expo­
sure through engineering controls, 
good work practices, and person­
al protective equipment (PPE) and 
provides education about working 
with hazardous drugs. Medical sur­
veillance involves collecting and in­
terpreting data to detect changes in 
the health status of working popu­
lations potentially exposed to haz­
ardous substances. The elements of 
a medical surveillance program are 
used to establish an initial baseline 
of workers’ health and then moni­
tor their future health as it relates to 
their potential exposure to hazard­
ous agents. This information can be 
used to identify and correct preven­
tion failures leading to disease. Ear­
ly identification of health problems 
can also benefit individual workers.
Description of 
Exposure
Drugs are considered hazardous if stud­
ies in animals or humans show that they 
have the potential to cause cancer, repro­
ductive toxicity, birth defects, or damage 
to organs at low doses [NIOSH 2004]. In 
the United States, an estimated 8 million 
healthcare workers are potentially ex­
posed to hazardous drugs or drug waste 
at their worksites [BLS 2011]. Healthcare 
workers who should be included in the 
medical surveillance program are work­
ers who may be exposed to hazardous 
drugs directly such as nurses, pharma­
cists, and pharmacy technicians; or oth­
er workers (e.g., nurses’ aides, laundry 
workers) who may come into contact 
with hazardous or patient waste [OSHA 
1999; NIOSH 2004; ASHP 2006; ONS 
2011]. Table 1 lists job titles that may in­
volve handling hazardous drugs. Work­
ers may be exposed to hazardous drugs 
when they create aerosols, generate dust, 
clean up spills, or touch contaminated 
surfaces when compounding, adminis­
tering, or disposing of hazardous drugs 
or patient waste [NIOSH 2004].
Exposure to hazardous drugs may oc­
cur through skin contact, inhalation, 
ingestion, or injection. Skin contact 
and inhalation are the most likely ways
Figure 1. Multi-channel infusion pump 
for delivery of chemotherapy.
Table 1. Job titles that may 
involve exposure to hazardous 
drugs:
1. Pharmacists and pharmacy 
technicians
2. Nurses (RNs, ARNPs, LPNs)
3. Physicians and physician assistants
4. Operating room personnel
5. Home healthcare workers
6. Veterinarians and veterinary 
technicians
7. Environmental service workers 
(housekeeping, laundry, mainte­
nance workers)
8. Workers who ship, transport, or 
receive hazardous drugs
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a worker may be exposed to hazardous drugs. However, in­
gestion (from hand to mouth) or injection through a needle 
stick or sharps injury is also possible.
Many hazardous drugs are used to treat illnesses such as 
cancer or HIV infection (see Figure 1). For the patients, 
the potential benefits of hazardous drug treatm ent out­
weigh the possible negative side effects. However, ex­
posed healthcare workers risk the same side effects with 
no benefit. Workers exposed to hazardous drugs have de­
veloped skin disorders, adverse reproductive effects, and 
possibly leukemia and other cancers. For example, nurses 
and pharmacists who were exposed to hazardous drugs at 
their worksite reported an increase in adverse reproduc­
tive events including spontaneous abortions, stillbirths, 
and congenital m alform ations compared with unexposed 
healthcare workers [NIOSH 2004]. A recent epidemiolog­
ical evaluation of nurses found a statistically significant, 
nearly 2-fold increase in risk for spontaneous abortion 
among those exposed to antineoplastic agents for more 
than 1 hour per day during the first trim ester [Lawson et. 
al. 2012].
Medical Surveillance
NIOSH recom m ends m edical surveillance of workers 
who handle hazardous materials and are therefore at risk 
of adverse health effects from exposure. The goal of m ed­
ical surveillance is to minimize adverse health effects in 
workers exposed to hazardous substances. By identify­
ing and correcting failures in exposure prevention (iden­
tified through medical surveillance), employers can lim ­
it exposure and prevent adverse health outcomes in other 
workers (prim ary prevention). In addition, by identify­
ing the earliest reversible biologic effects, exposure can 
be reduced or eliminated, and further adverse health ef­
fects can be limited in individual workers (secondary pre­
vention). Medical surveillance is a second line of defense, 
augmenting the protection afforded by engineering con­
trols, other administrative controls, work practice con­
trols, PPE, and worker education about the hazards of the 
m aterials they work with or they may come into contact 
with in the course of their duties [NIOSH 2004; 2009]. An 
effective surveillance program  begins with a hazard iden­
tification program  that is integrated with surveillance for 
disease or illness. The following types of data are often 
obtained and evaluated by medical surveillance programs:




Elements of a Medical 
Surveillance Program
Several important issues should be considered in designing 
a medical surveillance program for workers responsible for 
handling hazardous drugs. The first is to develop an organized 
approach to identifying workers who are potentially exposed 
to hazardous drugs on the basis of their job duties. The second 
is to provide medical surveillance that is appropriate to the ex­
posure because the various classes of hazardous drugs differ 
in their modes of action and may affect specific target organs. 
Because healthcare workers are typically exposed to numer­
ous hazardous drugs [NIOSH 2004; 2012], no single biolog­
ical monitor is suitable for all of these drugs. Organizations 
should use the information obtained through medical surveil­
lance to help affected workers and to identify and correct sys­
tem failures that may have resulted in harmful exposures.
Elements of a medical surveillance program for workers ex­
posed to hazardous drugs should include the following:
■ Reproductive and general health questionnaires com­
pleted at the time of hire and periodically thereafter (see 
ONS 2011 for a sample questionnaire). Unless inform a­
tion about relevant symptoms and medical events such 
as spontaneous abortions is deliberately sought, their 
occurrence is likely to go unreported. Opportunities to 
identify patterns of occurrence implying defects in en­
gineering controls, technique, or other preventive mea­
sures may be similarly missed.
■ History of drug handling as an estimate of prior and cur­
rent exposure, including dates of duty assignment relat­
ed to hazardous drugs and similar types of information.
■ A plan to provide initial baseline clinical evaluation, including 
appropriately targeted medical history, physical examination, 
and laboratory testing for workers identified as being poten­
tially exposed to hazardous drugs that anticipates their poten­
tial toxicities.
■ A follow-up plan as needed for workers who have shown 
health changes suggesting toxicity or who have experi­
enced an acute exposure (substantial skin contact or in­
halation exposure, cleaning a large spill [a broken IV bag, 
leaking IV line], etc.).
If clinical laboratory studies and/or biological monitoring is 
contemplated, a rational approach to selecting clinical stud­
ies would consider the toxicity patterns of the drugs to which 
workers are exposed.
Medical surveillance program results should be examined 
in aggregate for trends that may be a sign of health chang­
es because of exposure to hazardous drugs. If health changes 
are found during follow-up evaluations, the employer should 
take the following actions:
■ Evaluate current protective measures that are already 
in place:
— Engineering controls (Class II biological safety cab­
inets/compounding aseptic containment isolators, 
robotic systems, ventilation, closed system transfer 
devices, and closed IV systems).
■ Compare perform ance of controls with rec­
om m ended standards.
■ C onduct environm ental sampling when ana­
lytical m ethods are available.
— Policies for the use of PPE and worker com pli­
ance with PPE use and policies.
— Availability of appropriate PPE such as double 
gloves tested for use with hazardous drugs [ASTM 
2005], nonpermeable gowns, and respiratory pro­
tection [NIOSH 2009].
■ Verify that all controls are in proper operating condition 
and monitor worker compliance with existing policies or 
when new policies go into effect.
■ Develop a plan of action that will prevent further work­
er exposure.
■ Ensure confidential two-way communication between a 
worker and the employee health unit regarding notification:
— By any worker wishing to discuss a change in health 
condition such as pregnancy or chronic illness with 
the employee health unit, or
— By the health unit, when communicating the find­
ing of an adverse health effect and instructions for 
follow-up back to the workers.
■ If an employee health unit is not available for a facility, 
workers should be encouraged to address exposure issues 
with their primary medical provider.
■ Provide ongoing medical surveillance for all workers at 
risk to determine whether the new plan is effective.
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For More Information
NIOSH has published an Alert describing measures to con­
trol worker exposure to hazardous drugs: www.cdc.gov/niosh/ 
docs/2004-165/
Additional information about hazardous drugs is available 
on the NIOSH Web site at www.cdc.gov/niosh/topics/haz- 
drug/default.html. To receive copies of NIOSH publica­
tions, contact NIOSH at
Telephone: I - 8 OO-CDC-INFO (1-800-232-4636)
TTY: 1-888-232-6348 ■ E-mail: cdcinfo@cdc.gov
or visit the NIOSH Web site at www.cdc.gov/niosh
For a monthly update on news at NIOSH, subscribe to 
NIOSH eNews by visiting www.cdc.gov/niosh/eNews.
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This document is in the public domain and may be 
freely copied or reprinted. NIOSH encourages all 
readers of the Workplace Solutions to make them 
available to all interested employers and workers.
As part of the Centers for Disease C ontrol and Preven­
tion, NIOSH is the Federal agency responsible for con­
ducting research and making recommendations to prevent 
work-related illness and injuries. All Workplace Solutions 
are based on research studies that show how worker expo­
sures to hazardous agents or activities can be significant­
ly reduced.
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